このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Revance Therapeutics 将来の成長

Future 基準チェック /26

Revance Therapeutics利益と収益がそれぞれ年間68.8%と22.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-42.7% 71.4%なると予測されています。

主要情報

68.8%

収益成長率

71.4%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	22.6%
将来の株主資本利益率	-42.7%
アナリストカバレッジ	Good
最終更新日	05 Jun 2024

今後の成長に関する最新情報

Recent updates

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14

業績と収益の成長予測

NasdaqGM:RVNC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	475	-19	42	100	10
12/31/2025	372	-90	-45	0	11
12/31/2024	278	-190	-125	-43	11
3/31/2024	240	-325	-221	-213	N/A
12/31/2023	234	-324	-223	-217	N/A
9/30/2023	211	-403	-210	-204	N/A
6/30/2023	183	-346	-214	-211	N/A
3/31/2023	153	-341	-204	-202	N/A
12/31/2022	133	-356	-197	-194	N/A
9/30/2022	109	-274	-214	-208	N/A
6/30/2022	99	-263	-210	-203	N/A
3/31/2022	90	-274	-216	-208	N/A
12/31/2021	78	-281	-232	-222	N/A
9/30/2021	63	-297	-247	-239	N/A
6/30/2021	47	-303	-250	-242	N/A
3/31/2021	29	-292	-218	-210	N/A
12/31/2020	15	-282	-183	-179	N/A
9/30/2020	4	-249	-152	-150	N/A
6/30/2020	0	-209	-129	-126	N/A
3/31/2020	0	-186	-141	-138	N/A
12/31/2019	0	-159	-109	-106	N/A
9/30/2019	1	-155	-108	-104	N/A
6/30/2019	3	-146	-103	-97	N/A
3/31/2019	4	-143	-112	-105	N/A
12/31/2018	4	-143	-111	-104	N/A
9/30/2018	3	-138	-107	-102	N/A
6/30/2018	1	-136	-101	-98	N/A
3/31/2018	0	-128	-89	-85	N/A
12/31/2017	0	-121	N/A	-95	N/A
9/30/2017	0	-111	N/A	-80	N/A
6/30/2017	0	-99	N/A	-73	N/A
3/31/2017	0	-97	N/A	-65	N/A
12/31/2016	0	-89	N/A	-60	N/A
9/30/2016	0	-85	N/A	-63	N/A
6/30/2016	0	-86	N/A	-62	N/A
3/31/2016	0	-78	N/A	-58	N/A
12/31/2015	0	-73	N/A	-56	N/A
9/30/2015	0	-66	N/A	-48	N/A
6/30/2015	0	-60	N/A	-47	N/A
3/31/2015	0	-57	N/A	-47	N/A
12/31/2014	0	-63	N/A	-55	N/A
9/30/2014	1	-49	N/A	-60	N/A
6/30/2014	1	-48	N/A	-54	N/A
3/31/2014	1	-38	N/A	-62	N/A
12/31/2013	1	0	N/A	-48	N/A
9/30/2013	0	-10	N/A	-49	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RVNC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RVNC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RVNC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RVNCの収益 ( 22.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: RVNCの収益 ( 22.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RVNC 3 年以内に赤字になると予測されています。

Revance Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Forecast to breakeven in 2026

Price target decreased by 18% to US$16.33

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Recent updates

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Revance Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Price target decreased by 18% to US$16.33

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Price target decreased by 18% to US$29.25

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Price target decreased by 7.1% to US$33.67

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Price target decreased by 9.0% to US$36.25

Consensus EPS estimates fall by 13%

Senior VP notifies of intention to sell stock

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

CEO & Director notifies of intention to sell stock

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.4m worth of stock

Forecast to breakeven in 2025

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Principal Accounting Officer notifies of intention to sell stock

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.2m worth of stock

No longer forecast to breakeven

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Revance Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Revance Therapeutics, Inc. Submits Supplemental Biologics License Application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer

Revance Therapeutics, Inc. Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection in the Aesthetic Surgery Journal

Senior VP notifies of intention to sell stock